BioTrillion innovates at the intersection of 3 key domains:
Throughout history, the medical field has continuously innovated devices to obtain insights into the human body for disease detection. In the past, such insights were primarily accessed invasively. Today's innovations enable access to much of these insights non-invasively. The future will further this evolution, enabling access to these vital health insights, contactlessly.
This progression — from invasive, to non-invasive, to contactless — symbolizes the trend of innovation shifting away from the constraints of a physical paradigm, exponentially amplifying the convenience and scalability of accessing insights into our health.
Our digital biomarker journey began in Neurology — where "Human Eyes meet Machine Eyes meet AI." Human eyes are an anatomic extension of your brain. Machine eyes and AI, specifically smartphone optical hardware and neural networks, now enable us to objectively and quantiatively measure the most subtle features and patterns in your eyes that are clinically known to be windows into neurologic function and health. We subsequently expanded to the face, a "gold mine" of additional digital biomarkers.
Our AI-powered digital biomarkers can now measure 5 vital signs – familiar to clinicians for decades – from a simple 10-second face scan.
For privacy and security, we've also architected our technology to process and extract health metrics locally, ensuring your images never leave your smartphone.
Beyond serving as a "dashboard" of your organ level health, our suite of digital biomarkers now enable us to detect key combinations of signs expressed by several diseases, disorders, drug effects, and drug uses.
Our ability to measure diverse anatomic regions with incredible precision provide insights across all 3 vital organs of the body — brain, heart, lungs — confering several unique advantages:
The combination of text descriptions (symptoms) and biomarker measures (signs) in disease detection is crucial for a comprehensive understanding of physiology. OpenAI (ChatGPT) applies Generative AI to qualitative language, while BioTrillion applies Computer Vision AI to quantitative measures.
And with our upcoming integration of the OpenAI API in BioEngine4D, we will be able to unlock the synergy between qualitative and quantitative approaches to extraordinarily increase the timeliness and accuracy of our disease detection technology for ordinary consumers.
Our digital biomarkers provide value to multiple stakeholders in the healthcare ecosystem, from pharma, to providers, to payors, and to patients:
Moreover, our digital biomarker platform provides several enabling applications to industries beyond Health.
The camera hardware on smartphones represent a significant opportunity for consumer health applications. In order for the smartphone industry to continue its growth, it will need to offer novel applications to compel consumers to continue upgrading to newer models with better cameras. BioTrillion believes that the next "killer app" for smartphones is health.
Today, 8 billion humans around the world shed incredibly valuable health data every second, every day, all year.
In the near future, digital biomarkers and vital sign measuring solutions will make it obvious just how ineffective our traditional approaches to healthcare have been.
In retrospect, these solutions will make us realize that our health had been "in the dark" for 99% of our life.
© 2024 BioTrillion, Inc. | All Rights Reserved Worldwide | Terms of Use